medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2020, Number 07

<< Back Next >>

Ginecol Obstet Mex 2020; 88 (07)

Prevalence of infection by genotypes of the PVH in women with ASCUS cytology

Medina-Bueno GA

Language: Spanish
References: 18
Page: 437-441
PDF size: 190.03 Kb.


ABSTRACT

Objective: To estimate the prevalence of infection by genotypes of the human papilloma virus in women with squamous cell atypia of unknown significance (ASCUS).
Materials and Method: Transversal and cross-sectional study of patients referred to the Carlos Alberto Seguín National Hospital, during 2018, for presenting ASCUS cytology, the Genoarray-Hybribio system for genotyping was reported. The study variables were: high-risk HPV genotypes, low-risk HPV, and age. Proportions and odds ratios were estimated with 95% confidence intervals.
Results: 227 patients were studied, of which 95 had a positive test for HPV (41.8%). The prevalence for high-risk genotypes was 33.9%. The most frequent being 16, 31, 52 and 53. The prevalence was 4.8% for low-risk genotypes: 81, 6, 43, and 11, and 3.1% were mixed infections. 38 women had infection with less than two genotypes, women older than 30 years were 3 times more at risk of infection due to high-risk genotypes, Odss ratio 3.32 (95% CI 1.21-9.10) in relation to those younger than 30 years, statistical association significant p ‹0.01.
Conclusions: The overall prevalence was 41.8%, the high-risk HPV infection in women with ASCUS was 33.9%, with the genotypes most prevalent in single infections being 16, 31, 52, and 53.


REFERENCES

  1. Arbyn M, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020 Feb 8 (2): e191-e203. https://doi. org/10.1016/S2214-109X(19)30482-6

  2. Bruni L, et al. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010; 202 (12): 1789-99. https://doi.org/10.1086/657321

  3. Walboomers J, et al . Human papillomavi - rus is a necessary cause of invasive cerv i - cal cancer worldwide. J Pathol 1999; 189 (1): 12-9. https://doi.org/10. 1002/( SICI ) 1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F

  4. Piñeros M, et al. Cancer patterns, trends, and transitions in Peru: a regional perspectivel . The Lancet Oncology 2017; 18 (10): PE573-E586. https://doi.org/10.1016/S1470-2045(17)30377-7

  5. Robles C, et al. Alternative HPV vaccination schedules in Latin America. Salud Pública Mex. 2018; 60 (6): 693-702. https://doi.org/10.21149/9810

  6. Alameda F, et al. Citología en medio líquido (ThinPrep PapTest). Un año de experiencia. Prog Obstet Ginecol. 2007; 50 (4): 197-202. https://doi.org/10.1016/S0304- 5013(07)73173-4

  7. Srodon M, et al. Atypical Squamous Cells, Cannot Exclude High-Grade Squamous Intraepithelial Lesion: Diagnostic Performance, Human Papillomavirus Testing, and Follow-Up Results. Cancer 2006; 108 (1): 32-38. https://doi.org/10.1002/cncr.21388

  8. Martínez-Portilla RJ, et al. Prevalencia de serotipos de VPH de alto riesgo detectados por PCR en pacientes con citología normal del Hospital Regional Adolfo López Mateos, ISSSTE. Ginecol Obstet Mex 2016; 84 (9): 556-61.

  9. Heredia-Caballero A, et al. Prevalencia y tipificación de genotipos de virus del papiloma humano en mujeres del área metropolitana del Valle de México. Ginecol Obstet Mex. 2017; 85 (12): 809-18. https://doi.org/10.24245/ gom.v85i12.1537

  10. Liang M, et al. Characteristics of women infected with human papillomavirus in a tertiary Hospital in Beijing China, 2014-2018. BMC Infect Dis. 2019; 19(1). https:// doi.org/10.1186/s12879-019-4313-8

  11. Manrique-Hinojosa J, et al. Detección del virus del papiloma humano en muestras obtenidas mediante técnica de autotoma en un grupo de universitarias peruanas. Rev. perú. med. exp. salud publica 2018; 35 (4). https://doi.org/10.17843/rpmesp.2018.354.3450

  12. García S, et al. Detección del VPH en mujeres con y sin alteraciones citológicas del cérvix en Castilla y León: estudio poblacional. Ginecol Obstet Mex. 2017; 85 (4): 217-23.

  13. Salcedo M, et al. Human papillomavirus genotypes among females in Mexico: a study from the Mexican Institute for Social Security. Asian Pac J Cancer Prev. 2014; 15 (23): 10061-6. https://doi.org/10.7314/APJCP.2014.15.23.10061

  14. Paz-Zulueta M, et al. Prevalencia de genotipos no vacunados de alto riesgo del virus del papiloma humano en el programa de detección precoz del cáncer de cuello uterino en Cantabria. Aten Primaria. 2016; 48 (6): 347-55. https://doi.org/10.1016/j.aprim.2015.07.006

  15. Torres-Ibarra L, et al. Triage strategies in cervical cancer detection in Mexico: Methods of the FRIDA Study. Salud Publica Mex. 2016; 58 (2): 197-210. https://doi.org/10.21149/ spm.v58i2.7789

  16. Fernández-Montolí ME, et al. Long-term predictors of residual or recurrent cervical intraepithelial neoplasia 2-3 after treatment with a large loop excision of the transformation zone: a retrospective study. BJOG. 2020; 127 (3): 377-87. https://doi.org/10.1111/1471-0528.15996

  17. Tejada R, et al. Human papillomavirus vaccine efficacy in the prevention of anogenital warts: Systematic review and meta-analysis. Salud Publica Mex. 2017; 59 (1): 84-94. https://doi.org/10.21149/7824

  18. Egli-Gany D, et al. Human Papillomavirus Genotype distribution and socio-behavioural characteristics in women with cervical pre-cancer and cancer at the start of a human papillomavirus vaccination-programme: The CIN3+ Plus Study. BMC Cancer. 2019; 19 (1): 111. https://doi. org/10.1186/s12885-018-5248-y




2020     |     www.medigraphic.com